CONTEXT: Studies in adults have reported associations of low circulating total 25-hydroxyvitamin D with increased cardiovascular disease and risk factors. Evidence of associations in children, however, is limited, and it is unknown whether associations with risk factors differ for each 25-hydroxyvitamin D analog [25-hydroxyvitamin D(2) (25[OH]D(2)) and 25-hydroxyvitamin D(2) (25[OH]D(3))]. OBJECTIVE: The objective of the study was to compare associations of 25(OH)D(2) and 25(OH)D(3) with cardiovascular risk factors in children. DESIGN/ SETTING: The design of the study was a cross-sectional study of 4274 children (mean age 9.9 yr) from the Avon Longitudinal Study of Parents and Children. MAIN OUTCOMES: The main outcomes included blood pressure, lipids [triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C)], apolipoproteins (Apo-A1 and Apo-B), adiponectin, leptin, C-reactive protein, and IL-6. RESULTS: In confounder-adjusted models, 25(OH)D(2) was inversely associated with Apo-A1 (change per doubling of exposure: -0.74 mg/dl; 95% confidence interval -0.14, -0.04) and triglycerides (relative percentage change per doubling of exposure: -1.64%; -3.27, 0.01) and positively associated with C-reactive protein (8.42%; 3.40, 13.58) and IL-6 (5.75%; 1.83, 9.25). 25(OH)D(3) was positively associated with HDL-C (0.04 mmol/liter; 0.02, 0.06), Apo-A1 (1.96 mg/dl; 0.65, 3.24), and adiponectin (0.47 μg/ml; 0.15, 0.79). There was statistical evidence that associations of 25(OH)D(2) and 25(OH)D(3) with HDL-C, Apo-A1, and IL-6 differed from each other (all P values for differences ≤0.02). CONCLUSIONS: Higher circulating 25(OH)D(3) was associated with cardioprotective levels of HDL-C, Apo-A1, and adiponectin in children. Associations of 25(OH)D(2) with cardiovascular risk factors were in mixed directions. It is necessary to see whether these associations are replicated in large prospective studies.
CONTEXT: Studies in adults have reported associations of low circulating total 25-hydroxyvitamin D with increased cardiovascular disease and risk factors. Evidence of associations in children, however, is limited, and it is unknown whether associations with risk factors differ for each 25-hydroxyvitamin D analog [25-hydroxyvitamin D(2) (25[OH]D(2)) and 25-hydroxyvitamin D(2) (25[OH]D(3))]. OBJECTIVE: The objective of the study was to compare associations of 25(OH)D(2) and 25(OH)D(3) with cardiovascular risk factors in children. DESIGN/ SETTING: The design of the study was a cross-sectional study of 4274 children (mean age 9.9 yr) from the Avon Longitudinal Study of Parents and Children. MAIN OUTCOMES: The main outcomes included blood pressure, lipids [triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C)], apolipoproteins (Apo-A1 and Apo-B), adiponectin, leptin, C-reactive protein, and IL-6. RESULTS: In confounder-adjusted models, 25(OH)D(2) was inversely associated with Apo-A1 (change per doubling of exposure: -0.74 mg/dl; 95% confidence interval -0.14, -0.04) and triglycerides (relative percentage change per doubling of exposure: -1.64%; -3.27, 0.01) and positively associated with C-reactive protein (8.42%; 3.40, 13.58) and IL-6 (5.75%; 1.83, 9.25). 25(OH)D(3) was positively associated with HDL-C (0.04 mmol/liter; 0.02, 0.06), Apo-A1 (1.96 mg/dl; 0.65, 3.24), and adiponectin (0.47 μg/ml; 0.15, 0.79). There was statistical evidence that associations of 25(OH)D(2) and 25(OH)D(3) with HDL-C, Apo-A1, and IL-6 differed from each other (all P values for differences ≤0.02). CONCLUSIONS: Higher circulating 25(OH)D(3) was associated with cardioprotective levels of HDL-C, Apo-A1, and adiponectin in children. Associations of 25(OH)D(2) with cardiovascular risk factors were in mixed directions. It is necessary to see whether these associations are replicated in large prospective studies.
Authors: Jonathan N Hofmann; Kai Yu; Ronald L Horst; Richard B Hayes; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Kumaravel Rajakumar; Javier de las Heras; Tai C Chen; SoJung Lee; Michael F Holick; Silva A Arslanian Journal: J Clin Endocrinol Metab Date: 2011-03-02 Impact factor: 5.958
Authors: Emil Hagström; Per Hellman; Tobias E Larsson; Erik Ingelsson; Lars Berglund; Johan Sundström; Håkan Melhus; Claes Held; Lars Lind; Karl Michaëlsson; Johan Arnlöv Journal: Circulation Date: 2009-05-18 Impact factor: 29.690
Authors: Thomas J Wang; Michael J Pencina; Sarah L Booth; Paul F Jacques; Erik Ingelsson; Katherine Lanier; Emelia J Benjamin; Ralph B D'Agostino; Myles Wolf; Ramachandran S Vasan Journal: Circulation Date: 2008-01-07 Impact factor: 29.690
Authors: Kozeta Miliku; Janine F Felix; Trudy Voortman; Henning Tiemeier; Darryl W Eyles; Thomas H Burne; John J McGrath; Vincent W V Jaddoe Journal: Matern Child Nutr Date: 2018-09-21 Impact factor: 3.092
Authors: Katherine Tomaino; Karina M Romero; Colin L Robinson; Lauren M Baumann; Nadia N Hansel; Suzanne L Pollard; Robert H Gilman; Edward Mougey; John J Lima; William Checkley Journal: Am J Hypertens Date: 2015-01-19 Impact factor: 2.689
Authors: Catherine S Birken; Gerald Lebovic; Laura N Anderson; Brian W McCrindle; Muhammad Mamdani; Sharmilaa Kandasamy; Marina Khovratovich; Patricia C Parkin; Jonathon L Maguire Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Dylan M Williams; Abigail Fraser; William D Fraser; Elina Hyppönen; George Davey Smith; John Deanfield; Aroon Hingorani; Naveed Sattar; Debbie A Lawlor Journal: Heart Date: 2013-10-14 Impact factor: 5.994
Authors: Dylan M Williams; Abigail Fraser; Adrian Sayers; William D Fraser; Elina Hyppönen; George Davey Smith; Naveed Sattar; Debbie A Lawlor Journal: Eur J Prev Cardiol Date: 2012-11-26 Impact factor: 7.804
Authors: R D Lewis; E M Laing; K M Hill Gallant; D B Hall; G P McCabe; D B Hausman; B R Martin; S J Warden; M Peacock; C M Weaver Journal: J Clin Endocrinol Metab Date: 2013-10-03 Impact factor: 5.958